Skip to main content
Xcell Therapeutics Inc. logo

Xcell Therapeutics Inc. — Investor Relations & Filings

Ticker · 373110 ISIN · KR7373110006 KO Manufacturing
Open in API
Filings indexed 86 across all filing types
Latest filing 2024-06-04 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 373110

About Xcell Therapeutics Inc.

https://www.xcell.co.kr/

Xcell Therapeutics Inc. is a company specializing in the research, development, and production of advanced cell culture media. Its primary product line, CellCor™, consists of serum-free, chemically defined media designed to provide an optimal environment for cell culture, particularly for mesenchymal stem cells (MSCs). The technology aims to enhance efficiency and yield for researchers and developers in the fields of cell therapy and regenerative medicine. By offering a serum-free alternative, the company provides a more consistent and defined solution compared to traditional media. Xcell Therapeutics is also expanding its services to become a Contract Development and Manufacturing Organization (CDMO) and is exploring applications for its media in the cultured meat sector.

Recent filings

Filing Released Lang Actions
[기재정정]증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a 'Securities Registration Statement' (증권신고서) amendment (정정신고) filed by Excel Therapeutics. It details changes to the public offering schedule, including demand forecasting, subscription dates, and payment dates. In the context of financial filings, a Securities Registration Statement is a primary regulatory document for capital raising. Since it is a formal regulatory filing detailing the terms of a share issuance and capital change, it falls under the 'Share Issue/Capital Change' category.
2024-06-04 Korean
분기보고서 (2024.03)
Interim / Quarterly Report Classification · 100% confidence The document is a 'Quarterly Report' (분기보고서) for the company 'Xcell Therapeutics' (주식회사 엑셀세라퓨틱스) covering the period from January 1, 2024, to March 31, 2024. It contains detailed financial statements, management discussion and analysis, and corporate governance information, which aligns with the definition of an Interim/Quarterly Report (IR). Q1 2024
2024-05-13 Korean
증권신고서(지분증권)
Share Issue/Capital Change Classification · 95% confidence The document is a '증권신고서' (Securities Registration Statement) filed by Xcell Therapeutics with the Financial Services Commission (FSC) in South Korea. It details the company's intent to offer shares (1,618,000 common shares), provides comprehensive risk factors, business descriptions, and financial information required for a public offering (IPO). This document is a formal regulatory filing for a capital raise, which falls under the 'Regulatory Filings' category as it is a primary registration document for securities.
2024-05-13 Korean
주요사항보고서(유형자산양도결정)
Regulatory Filings Classification · 100% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Financial Services Commission in South Korea. It specifically details a 'Decision to Dispose of Tangible Assets' (유형자산 양도 결정), which involves the sale of land and buildings to improve financial liquidity and repay debt. This type of regulatory disclosure regarding significant corporate asset transactions falls under the 'Regulatory Filings' category as it is a specific material event disclosure that does not fit into the other specialized categories like M&A or share issuance.
2024-04-03 Korean
사업보고서 (2023.12)
Annual Report Classification · 100% confidence The document is a 'Business Report' (사업보고서) for the fiscal year 2023 (Jan 1, 2023 to Dec 31, 2023) for Xcell Therapeutics Inc. It contains comprehensive financial statements, management discussion and analysis, governance information, and operational details. This is the standard Korean regulatory filing equivalent to a 10-K in the US market. FY 2023
2024-03-29 Korean
감사보고서 (2022.12)
Audit Report / Information Classification · 100% confidence The document is a formal 'Audit Report' (감사보고서) for Excel Therapeutics (엑셀세라퓨틱스) for the fiscal year ending December 31, 2022. It includes the independent auditor's opinion, financial statements (balance sheet, income statement, statement of changes in equity, cash flow statement), and detailed notes to the financial statements. This is a comprehensive financial document, not an announcement or a summary, and fits the definition of an Audit Report/Information (AR). FY 2022
2023-03-31 Korean

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.